𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin

✍ Scribed by Hans Carl Hasselbalch; Nielsaage Tøffner Clausen; Bjarne Anker Jensen

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
205 KB
Volume
70
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human erythropoietin for the
Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors
✍ León, Pedro; Jiménez, Miguel; Barona, Pascual; Sierrasesúmaga, Luis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Background. Cancer is often associated with chronic anemia which frequently requires blood transfusions. This study was performed to assess the efficacy and safety of r-HuEPO therapy in children with cancer. Patients and methods. Twenty-five patients under 18 years of age with solid malignant

Anemia associated with advanced prostati
Anemia associated with advanced prostatic adenocarcinoma: Effects of recombinant human erythropoietin
✍ Beshara, Soheir; Letocha, Henry; Linde, Torbjörn; Wikström, Björn; Sandhagen, Bo 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

## BACKGROUND AND METHODS. Nine patients with hormone-refractory metastatic prostatic adenocarcinoma and anemia were treated with recombinant human erythropoietin (rHuEpo) at a median dose of 150 U/kg BW 3 times a week subcutaneously. Baseline hemoglobin (Hb) ranged from 70 to 116 g/L, and the stu

Combination Therapy With Recombinant Hum
Combination Therapy With Recombinant Human Granulocyte Colony-Stimulating Factor and Erythropoietin in Aplastic Anemia
✍ Dr. Masahiro Imamura; Masanobu Kobayashi; Sumiko Kobayashi; Kohki Yoshida; Chika 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB

## Abstract Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) and erythropoietin (rhEPO) were used to treat patients with aplastic anemia (AA). In terms of effects on erythrocyte recovery, the combined use of rhG‐CSF and rhEPO showed a favorable response in 6 of 14 (42.9%) patients